Published in Gene Ther on August 10, 2006
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
Targeting cancer-initiating cells with oncolytic viruses. Mol Ther (2009) 1.18
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev (2010) 1.06
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging. Mol Imaging (2010) 0.84
Evaluation of adenovirus capsid labeling versus transgene expression. Virol J (2010) 0.78
Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines. Int J Clin Exp Pathol (2015) 0.76
Promising oncolytic agents for metastatic breast cancer treatment. Oncolytic Virother (2015) 0.76
Effect of adenoviral delivery of prodynorphin gene on experimental inflammatory pain induced by formalin in rats. Int J Clin Exp Med (2014) 0.75
shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy. Oncotarget (2016) 0.75
Cancer cell cycles. Science (1996) 21.29
Molecular imaging. Radiology (2001) 5.67
Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer (2002) 3.36
Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology (1987) 2.85
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol (1997) 2.64
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med (2000) 2.24
AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther (2004) 2.15
Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther (2001) 1.96
Replicative adenoviruses for cancer therapy. Nat Biotechnol (2000) 1.89
Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis (2003) 1.86
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol (2001) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther (2003) 1.63
Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci U S A (2003) 1.61
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res (2001) 1.55
High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer (2003) 1.49
Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest (1998) 1.46
Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol (2001) 1.43
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist (2004) 1.37
Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res (2002) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res (2001) 1.20
Modified adenoviruses for cancer gene therapy. Int J Cancer (2004) 1.18
The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res (2002) 1.17
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther (2001) 1.10
Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther (2004) 1.04
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol (2002) 1.03
Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer (2003) 0.95
Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biol (2003) 0.95
Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res (2001) 0.95
Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues. J Pathol (1996) 0.94
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med (2004) 0.91
Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements. Cancer Genet Cytogenet (2005) 0.91
Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinoma cells. Exp Cell Res (2004) 0.89
Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res (1999) 0.88
A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells. Cancer Res (2004) 0.87
Adenoviruses in oncology: a viable option? BioDrugs (2002) 0.83
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther (2003) 0.82
Comparative transductions of breast cancer cells by three DNA viruses. Biochem Biophys Res Commun (2003) 0.80
Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol (2005) 0.80
Multicellular tumor spheroids in gene therapy and oncolytic virus therapy. Curr Opin Mol Ther (2004) 0.79
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Retracted Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet (2005) 3.13
Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res (1998) 2.92
Structure of the human cyclo-oxygenase-2 gene. Biochem J (1994) 1.97
Critical residues of Semliki Forest virus RNA capping enzyme involved in methyltransferase and guanylyltransferase-like activities. J Virol (1997) 1.86
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 1.85
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet (1999) 1.79
LKB1 somatic mutations in sporadic tumors. Am J Pathol (1999) 1.79
Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res (1996) 1.77
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res (1998) 1.75
The alphavirus replicase protein nsP1 is membrane-associated and has affinity to endocytic organelles. Virology (1995) 1.58
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res (1997) 1.47
The insulin gene promoter. A simplified nomenclature. Diabetes (1995) 1.39
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene (2007) 1.39
Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet (1998) 1.27
Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol (2011) 1.26
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res (2001) 1.24
Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci (1993) 1.23
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther (2010) 1.19
Effects of palmitoylation of replicase protein nsP1 on alphavirus infection. J Virol (2000) 1.19
Role of telomerase in cell senescence and oncogenesis. Annu Rev Med (2000) 1.18
Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res (1995) 1.18
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther (2011) 1.16
Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer (1997) 1.15
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol (1998) 1.13
SMAD genes in juvenile polyposis. Genes Chromosomes Cancer (1999) 1.10
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther (2005) 1.08
Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry (2001) 1.07
Vascular endothelial growth factor in human preterm lung. Am J Respir Crit Care Med (1999) 1.07
Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res (1991) 1.07
Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer (2011) 1.06
Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther (2004) 1.04
Crystal-structure-dependent photoluminescence from InP nanowires. Nanotechnology (2006) 1.02
Binding of Escherichia coli S fimbriae to cultured human endothelial cells. Infect Immun (1989) 1.02
Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J Biol Chem (1997) 1.02
Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans (2007) 1.01
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer (2008) 1.01
Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Endocrinology (1997) 1.01
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer (2011) 0.99
Oncolytic adenovirus based on serotype 3. Cancer Gene Ther (2010) 0.99
Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates. Int J Cancer (1996) 0.99
Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol (1996) 0.98
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res (2001) 0.98
Random mutagenesis used to probe the structure and function of Bacillus stearothermophilus alpha-amylase. Protein Eng (1990) 0.97
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther (2005) 0.97
Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol (1996) 0.95
Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochem Biophys Res Commun (1990) 0.94
Molecular control of transgene escape from genetically modified plants. Plant Sci (2001) 0.92
Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol (2001) 0.92
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther (2007) 0.91
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 0.91
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol (2006) 0.90
Green fluorescent protein (GFP) fusion constructs in gene therapy research. Histochem Cell Biol (2001) 0.90
Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology (2004) 0.89
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut (2003) 0.88
Time trends in survival from cancer of unknown primary: small steps forward. Eur J Cancer (2013) 0.88
In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. Int J Cancer (2013) 0.88
The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol (2007) 0.88
Genetic changes in the RNA components of RNase MRP and RNase P in Schmid metaphyseal chondrodysplasia. J Med Genet (2003) 0.88
Induction of cyclooxygenase-2 and prostaglandin F2alpha receptor expression by interleukin-1beta in cultured human granulosa-luteal cells. Endocrinology (1997) 0.87
Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res (2001) 0.87
Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther (2003) 0.87
Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation (2001) 0.86
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther (2004) 0.86
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol (2001) 0.86
Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol (2006) 0.86
Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br J Cancer (1997) 0.86
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther (2008) 0.86
PTEN expression is maintained in sporadic colorectal tumours. J Pathol (2001) 0.86
Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysis. Eur J Immunol (1988) 0.85
Expression of cyclooxygenase-2 and prostanoid receptors by human myometrium. J Clin Endocrinol Metab (2000) 0.85
Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells. Br J Pharmacol (1998) 0.85
Regulated expression of prostaglandin E(2) receptors EP2 and EP4 in human ovarian granulosa-luteal cells. J Clin Endocrinol Metab (2001) 0.85
Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries? Ann Oncol (2012) 0.84
Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3-year follow-up. Radiology (1994) 0.84
The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene (2000) 0.84
Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther (2011) 0.84
Genomic signatures of breast cancer metastasis. Cytogenet Genome Res (2007) 0.84
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther (2007) 0.83
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res (2001) 0.83